Reaching Your Target Weight on Mounjaro: What Comes Next

Why the body does not simply stay where it lands

A common assumption is that once you hit a target weight, the hardest work is done and the result will hold. That assumption is worth examining gently, because the biology tells a different story. Tirzepatide suppresses appetite and slows gastric emptying by activating two receptor pathways that your body's own hormones ordinarily manage — it does not retrain those pathways, it works alongside them. Clinical data from the SURMOUNT-1 trial, published in the New England Journal of Medicine, showed average weight reductions of around 20% at the 15 mg dose over 72 weeks. But extension and discontinuation data from similar GLP-1 programmes show that a meaningful proportion of that weight returns within 12 months of stopping, at a rate that varies by individual metabolic factors and how much lifestyle change has been embedded. This is not a failure of willpower. Obesity is a chronic condition shaped by hormonal set-points that are genuinely altered by treatment, and the body actively works to restore its prior state when treatment ends. Understanding this is the starting point for making a sensible plan at goal weight.

The picture when you stop Mounjaro depends heavily on what you were doing alongside treatment, your starting point, and how long you were on it. It is not uniform, which is why a one-size approach to discontinuation does not exist.

The three options your prescriber will consider with you

Clinically, reaching goal weight on Mounjaro opens three broad paths, and a good prescriber will walk through each rather than defaulting to one.

Continue at the current or lowest effective dose. Some people treat Mounjaro as ongoing weight-maintenance medicine, staying on the dose at which appetite regulation is maintained with the fewest side effects. This is a legitimate clinical approach, particularly where the comorbidity that triggered treatment (hypertension, obstructive sleep apnoea, dyslipidaemia) remains a concern even at target weight. It does, of course, carry ongoing cost and requires regular clinical review. Information on how Mounjaro is structured as a treatment is a useful primer before that conversation.

Taper to a lower dose. Some prescribers try stepping back down the titration schedule to find the minimum dose that maintains weight. This is pragmatic and reduces cost and medicine exposure, but requires close monitoring: if appetite and weight start to creep, moving back up promptly tends to recover the position more effectively than waiting.

Stop treatment. This is appropriate for some patients, particularly those who have made robust dietary and physical-activity changes and are in a good metabolic position. The NHS notes that the question of stopping should be reviewed carefully and that continued clinical input is valuable even after the prescription ends. Honest preparation for the likelihood of some weight return is part of that conversation. You can read a fuller breakdown of what stopping Mounjaro involves if this is the route you are considering.

What actually drives whether the weight stays off

The evidence suggests the people who maintain most of their weight loss after goal are those who have used the appetite-suppression window actively: building consistent higher-protein eating patterns, finding sustainable activity they will continue, and addressing the situational triggers that drove overeating. These are not easy things, and Mounjaro does not do them automatically. What it does is reduce the noise from hunger enough that the window is there. The NHS Better Health programme and a registered dietitian are genuinely useful supports at this stage. Mounjaro as a treatment is described in detail on our Mounjaro injection page, including how the medicine works across the dose schedule.

Cost is also a practical consideration at maintenance. Private treatment pricing for Mounjaro reflects the dose dispensed and the prescription review cycle; some people find a lower maintenance dose reduces the monthly outlay significantly. The broader range of weight-loss treatment options is worth reviewing at this stage too, because goal weight is a natural point to reassess the whole plan, not just the dose.

What clinical review looks like at this stage with nume

At nume, every repeat order is reviewed by a GPhC-registered prescriber before it is dispensed. That clinical re-review is what happens when you reach your goal: your prescriber looks at current weight, any changes in health since starting, and which of the three paths above makes sense for you. There is no auto-renewal, no subscription that carries on quietly, and no algorithm making that call. A real clinician reads your case. For people considering whether to taper, maintain or stop, that review is the right place to make the decision, reaching your goal weight on Mounjaro is not the end of the clinical relationship, it is a pivot point within it. If you are approaching that point and haven't yet discussed next steps, our team is available seven days a week.